Sheldon WR, et al. - Efficacy, safety/side effects and acceptability of buccal vs sublingual administration of a misoprostol-only regimen commonly used for early medical abortion were determined via performing a randomized trial at six clinics in two Latin American countries. Four hundred and one women who were seeking an early abortion were randomized to buccal or sublingual administration of three doses of misoprostol 800 mcg repeated every three hours; 202 into the buccal arm and 199 into the sublingual arm. Findings revealed reduced continuing pregnancy risk in correlation with sublingual administration relative to buccal administration after a three-dose regimen of 800 mcg misoprostol. The groups were comparable in terms of complete abortion rates. In both cases, increased success rates were noted with additional misoprostol at follow-up.